The marketing of foods and non-alcoholic beverages to children. Setting the research agenda

J. Halford,E. Boyland

DOI: https://doi.org/10.1016/j.appet.2012.12.003

IF: 5.016

2013-03-01

Appetite

Abstract:

What problem does this paper attempt to address?

The Babyccino: The Role of Caffeine in the Prevention of Acute Kidney Injury in Neonates—A Literature Review

Nimisha Aithal,Yogavijayan Kandasamy

DOI: https://doi.org/10.3390/healthcare12050529

2024-02-24

Health Care

Abstract:Acute kidney injury (AKI) in neonates is associated with increased morbidity and mortality. Theophylline (a methylxanthine) has been shown to prevent neonatal AKI but is seldom used due to its unfavorable profile. Caffeine, another methylxanthine, is utilized ubiquitously to treat apnea of prematurity, but there are no randomized trials evaluating its efficacy in preventing neonatal AKI. This literature review aims to summarize the existing research pertaining to the relationship between caffeine and neonatal AKI. The review was conducted using Pubmed, Embase, Google Scholar, and Cochrane. Inclusion criteria incorporated empirical studies, being published in English, and being available electronically. All eight studies identified were included. Seven studies found caffeine-exposed premature neonates had lower rates of AKI than caffeine-unexposed neonates. Four found reduced AKI severity with caffeine exposure. One study included term neonates and did not find a difference in the AKI rate between caffeine-exposed and non-exposed babies. Limitations include exclusively observational studies, short study periods, heterogenous definitions of prematurity, and a lack of assessment of dose–effect relationships. In conclusion, premature neonates exposed to caffeine appear to have lower rates and potentially less severe AKI. Further research is needed before caffeine can be considered for use in the primary prevention of neonatal AKI.

health care sciences & services,health policy & services
Caffeine Prevents Hyperoxia-Induced Lung Injury in Neonatal Mice Through NLRP3 Inflammasome and NF-κB Pathway.

Shangqin Chen,Qiuping Wu,Dingjuan Zhong,Changchong Li,Lizhong Du

DOI: https://doi.org/10.1186/s12931-020-01403-2

IF: 5.8

2020-01-01

Respiratory Research

Abstract:Background Bronchopulmonary dysplasia (BPD) is a common chronic lung disease in premature infants and hyperoxia exposure is a major cause. In hyperoxic lung injury animal model, alveolar simplification and pro-inflammatory cells infiltration are the main pathophysiologic changes. Caffeine is a drug used to treat apnea in premature infants. Early use of caffeine can decrease the rate and the severity of BPD while the mechanisms are still unclear. The purpose of this study was to evaluate the effects of caffeine on inflammation and lung development in neonatal mice with hyperoxic lung injury and to explore the possible mechanism. Methods Following 14 d of 75% oxygen exposure in newborn mouse, the BPD model was established. Caffeine at a dose of 1 g/L was added in drinking water to nursing mouse. We measured the concentration of caffeine in serum and oxidative stress in lung by commercially available kits. Adenosine 2A receptor (A 2A R) expression and lung inflammation were measured by Immunohistochemistry and western blotting. Apoptosis and surfactant protein-C (SFTPC) levels were measured by immunofluorescence. The inflammasome and NF-κB pathway proteins were assessed by western blotting. Results We found that the caffeine concentration in plasma at present dose significantly decreased the expression of A 2A R protein in mice lung. Caffeine treatment significantly reduced oxidative stress, improved weight gain, promoted alveolar development, attenuated inflammatory infiltration and lung injury in hyperoxia-induced lung injury mice. Moreover, caffeine decreased the cell apoptosis in lung tissues, especially the Type II alveolar epithelial cell. The expression of NLRP3 inflammasome protein and NF-κB pathway were significantly inhibited by caffeine treatment. Conclusion Caffeine treatment can protect hyperoxia-induced mice lung from oxidative injury by inhibiting NLRP3 inflammasome and NF-κB pathway.
Association Between Early Caffeine Citrate Administration and Risk of Acute Kidney Injury in Preterm Neonates: Results From the AWAKEN Study

Matthew W Harer,David J Askenazi,Louis J Boohaker,J Bryan Carmody,Russell L Griffin,Ronnie Guillet,David T Selewski,Jonathan R Swanson,Jennifer R Charlton,Neonatal Kidney Collaborative (NKC),Namasivayam Ambalavanan,Subrata Sarkar,Alison Kent,Jeffery Fletcher,Carolyn L. Abitbol,Marissa DeFreitas,Shahnaz Duara,Patrick Brophy,Carl D’Angio,Ayesa Mian,Erin Rademacher,Maroun J. Mhanna,Rupesh Raina,Deepak Kumar,Ayse Akcan Arikan,Christopher J. Rhee,Stuart L. Goldstein,Amy T. Nathan,Juan C. Kupferman,Alok Bhutada,Shantanu Rastogi,Elizabeth Bonachea,John Mahan,Arwa Nada,Susan Ingraham,Jennifer Jetton,Tarah T. Colaizy,Jonathan M. Klein,F. Sessions Cole,T. Keefe Davis,Joshua Dower,Lawrence Milner,Alexandra Smith,Kimberly Reidy,Frederick J. Kaskel,Jason Gien,Katja M. Gist,Mina H. Hanna,Craig S. Wong,Catherine Joseph,Tara DuPontAmy,Amy Staples,Robin Ohls,Surender Khokhar,Sofia Perazzo,Patricio E. Ray,Mary Revenis,Cherry Mammen,Anne Synnes,Pia Wintermark,Michael Zappitelli,Sidharth K. Sethi,Sanjay Wazir,Smriti Rohatgi,Danielle E. Soranno,Aftab S. Chishti,Robert Woroniecki,Shanty Sridhar

DOI: https://doi.org/10.1001/jamapediatrics.2018.0322

2018-06-04

Abstract:Importance: Acute kidney injury (AKI) occurs commonly in preterm neonates and is associated with increased morbidity and mortality. Objectives: To examine the association between caffeine citrate administration and AKI in preterm neonates in the first 7 days after birth and to test the hypothesis that caffeine administration would be associated with reduced incidence and severity of AKI. Design, setting, and participants: This study was a secondary analysis of the Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates (AWAKEN) study, a retrospective observational cohort that enrolled neonates born from January 1 to March 31, 2014. The dates of analysis were October 2016 to December 2017. The setting was an international, multicenter cohort study of neonates admitted to 24 participating level III or IV neonatal intensive care units. Participants met the original inclusion and exclusion criteria of the AWAKEN study. Additional exclusion criteria for this study included participants greater than or equal to 33 weeks' gestation at birth, admission after age 7 days, use of theophylline in the neonatal intensive care unit, or lack of data to define AKI. There were 675 preterm neonates available for analysis. Exposure: Administration of caffeine in the first 7 days after birth. Main outcomes and measures: The primary outcome was the incidence of AKI (based on the modified neonatal Kidney Disease: Improving Global Outcomes [KDIGO] definition) in the first 7 days after birth. The hypothesis that caffeine administration would be associated with reduced AKI incidence was formulated before data analysis. Results: The study cohort (n = 675) was 55.4% (n = 374) male, with a mean (SD) gestational age of 28.9 (2.8) weeks and a mean (SD) birth weight of 1285 (477) g. Acute kidney injury occurred in 122 neonates (18.1%) in the first 7 days after birth. Acute kidney injury occurred less frequently among neonates who received caffeine than among those who did not (50 of 447 [11.2%] vs 72 of 228 [31.6%], P < .01). After multivariable adjustment, administration of caffeine remained associated with reduced odds of developing AKI (adjusted odds ratio, 0.20; 95% CI, 0.11-0.34), indicating that for every 4.3 neonates exposed to caffeine one case of AKI was prevented. Among neonates with early AKI, those receiving caffeine were less likely to develop stage 2 or 3 AKI (adjusted odds ratio, 0.20; 95% CI, 0.12-0.34). Conclusions and relevance: Caffeine administration in preterm neonates is associated with reduced incidence and severity of AKI. Further studies should focus on the timing and dosage of caffeine to optimize the prevention of AKI.
Caffeine Citrate for Apnea of Prematurity: A Prospective, Open-Label, Single-Arm Study in Chinese Neonates

Lizhong Du,Xiaomei Tong,Chao Chen,Xirong Gao,Alessandra Gagnatelli,Jingyang Li,Debora Santoro,Sara Nicolardi,Laura Fabbri

DOI: https://doi.org/10.3389/fped.2020.00076

IF: 3.569

2020-01-01

Frontiers in Pediatrics

Abstract:Background: Caffeine citrate has been approved in China for the management of apnea of prematurity. This clinical trial was conducted as a condition of regulatory approval. The aim was to confirm the efficacy of caffeine citrate in the treatment of recurrent intermittent hypoxia and bradycardia in preterm newborns with primary apnea. Objectives: The primary outcome was the change from baseline in the number of apnea events after loading dose administration of caffeine citrate. Secondary efficacy outcomes included the change from baseline in apnea events after 2 and 4 weeks of maintenance doses. Methods: This was a multicenter, prospective longitudinal open-label, single-arm study. Neonates who had experienced at least four apnea events during a 24 h period received a loading dose of caffeine citrate 20 mg/kg; those who required additional maintenance doses received 5 mg/kg/day (titrated up to 10 mg/kg/day in case of insufficient response). The number of apnea events was recorded for 6-12 h prior to the loading dose (baseline), and for 12 h post-dose, following the loading dose and at Weeks 2 and 4 (during maintenance). Results: A total of 247 neonates received the loading dose, who had a significant reduction from baseline of 3.9 events (p < 0.001) in the mean number of apnea events. The subset of neonates who required maintenance doses also had significant reductions in the number of events at all visits (p < 0.001 for all). A total of 79.4% of participants had at least one adverse event, but only one non-serious and no serious events were considered related to treatment. Conclusions: In this large, prospective, open-label study, premature infants with a history of apnea who received caffeine citrate were significantly less likely to experience further apnea events.
Encephalopathy in Preterm Infants: Advances in Neuroprotection With Caffeine

Liu Yang,Xuefei Yu,Yajun Zhang,Na Liu,Xindong Xue,Jianhua Fu

DOI: https://doi.org/10.3389/fped.2021.724161

IF: 3.569

2021-10-01

Frontiers in Pediatrics

Abstract:With the improvement in neonatal rescue technology, the survival rate of critically ill preterm infants has substantially increased; however, the incidence of brain injury and sequelae in surviving preterm infants has concomitantly increased. Although the etiology and pathogenesis of preterm brain injury, and its prevention and treatment have been investigated in recent years, powerful and effective neuroprotective strategies are lacking. Caffeine is an emerging neuroprotective drug, and its benefits have been widely recognized; however, its effects depend on the dose of caffeine administered, the neurodevelopmental stage at the time of administration, and the duration of exposure. The main mechanisms of caffeine involve adenosine receptor antagonism, phosphodiesterase inhibition, calcium ion activation, and γ-aminobutyric acid receptor antagonism. Studies have shown that there are both direct and indirect beneficial effects of caffeine on the immature brain. Accordingly, this article briefly reviews the pharmacological characteristics of caffeine, its mechanism of action in the context of encephalopathy in premature infants, and its use in the neuroprotection of encephalopathy in this patient population.

pediatrics
Caffeine: The Story beyond Oxygen-Induced Lung and Brain Injury in Neonatal Animal Models—A Narrative Review

Stefanie Endesfelder

DOI: https://doi.org/10.3390/antiox13091076

IF: 7.675

2024-09-04

Antioxidants

Abstract:Caffeine is one of the most commonly used drugs in intensive care to stimulate the respiratory control mechanisms of very preterm infants. Respiratory instability, due to the degree of immaturity at birth, results in apnea of prematurity (AOP), hyperoxic, hypoxic, and intermittent hypoxic episodes. Oxidative stress cannot be avoided as a direct reaction and leads to neurological developmental deficits and even a higher prevalence of respiratory diseases in the further development of premature infants. Due to the proven antioxidant effect of caffeine in early use, largely protective effects on clinical outcomes can be observed. This is also impressively observed in experimental studies of caffeine application in oxidative stress-adapted rodent models of damage to the developing brain and lungs. However, caffeine shows undesirable effects outside these oxygen toxicity injury models. This review shows the effects of caffeine in hyperoxic, hypoxic/hypoxic-ischemic, and intermittent hypoxic rodent injury models, but also the negative effects on the rodent organism when caffeine is administered without exogenous oxidative stress. The narrative analysis of caffeine benefits in cerebral and pulmonary preterm infant models supports protective caffeine use but should be given critical consideration when considering caffeine treatment beyond the recommended corrected gestational age.

biochemistry & molecular biology,chemistry, medicinal,food science & technology
Caffeine for apnea and prevention of neurodevelopmental impairment in preterm infants: systematic review and meta-analysis

Elizabeth A. Oliphant,Sara M. Hanning,Christopher J. D. McKinlay,Jane M. Alsweiler

DOI: https://doi.org/10.1038/s41372-024-01939-x

2024-03-31

Journal of Perinatology

Abstract:This systematic review and meta-analysis evaluated the evidence for dose and effectiveness of caffeine in preterm infants. MEDLINE, EMBASE, CINHAL Plus, CENTRAL, and trial databases were searched to July 2022 for trials randomizing preterm infants to caffeine vs. placebo/no treatment, or low (≤10 mg·kg −1 ) vs. high dose (>10 mg·kg −1 caffeine citrate equivalent). Two researchers extracted data and assessed risk of bias using RoB; GRADE evaluation was completed by all authors. Meta-analysis of 15 studies (3530 infants) was performed in REVMAN across four epochs: neonatal/infant (birth-1 year), early childhood (1–5 years), middle childhood (6–11 years) and adolescence (12–19 years). Caffeine reduced apnea (RR 0.59; 95%CI 0.46,0.75; very low certainty) and bronchopulmonary dysplasia (0.77; 0.69,0.86; moderate certainty), with higher doses more effective. Caffeine had no effect on neurocognitive impairment in early childhood but possible benefit on motor function in middle childhood (0.72; 0.57,0.91; moderate certainty). The optimal dose remains unknown; further long-term studies, are needed.

pediatrics,obstetrics & gynecology
Individuals With Patellofemoral Pain Have Less Hip Flexibility Than Controls Regardless of Treatment Outcome

Karrie L. Hamstra-Wright,Jennifer E. Earl-Boehm,Lori A. Bolgla,C. Emery,R. Ferber

DOI: https://doi.org/10.1097/JSM.0000000000000307

2017-03-01

Abstract:Objective: To examine differences in hip flexibility before and after a 6-week muscle strengthening program between those with patellofemoral pain (PFP) and healthy controls. Design: Single-blind, multicentered, randomized controlled trial. Setting: Four clinical research laboratories. Subjects: Physically active individuals (199 PFP and 38 controls). Interventions: Patellofemoral pain and control subjects were randomized into either a hip-focused or a knee-focused muscle strengthening treatment program. Main Outcome Measures: Pain—visual analog scale (centimeter), function—Anterior Knee Pain Scale (points), flexibility—passive goniometry (degrees): hip adduction (HADD), hip external rotation (HER), hip internal rotation (HIR), total hip rotation (HROT), hip extension (HEXT) were measured before and after the muscle strengthening treatment program. Results: Subjects with patellofemoral pain who successfully completed the treatment program (n = 153) had 65%, 25%, 18%, and 12% less HADD, HER, HROT, and HIR ranges of motion (ROMs), respectively, than controls (P < 0.05). Patellofemoral pain subjects who did not successfully complete the program (n = 41) had 134%, 31%, 22%, and 13% less HADD, HER, HROT, and HIR ROMs, respectively, than controls (P < 0.05). All subjects increased their HIR, HROT, and HEXT ROMs pretest to posttest (P < 0.05), but by less than 2 degree. Conclusions: Individuals with PFP had less hip flexibility than controls regardless of treatment outcome or time. After the 6-week muscle strengthening program, and regardless of treatment success, PFP and control subjects experienced a small but clinically insignificant improvement in hip flexibility. Clinical Relevance: Hip ROM should be considered as a targeted area of focus in a rehabilitation program for physically active individuals with PFP.
Caffeine citrate improves outcomes of apnea of prematurity based on gestational ages

Dongchi Zhao,Li Lijun,Wang Xia,Yang Pu,Zheng Junwen

DOI: https://doi.org/10.21203/rs.2.12945/v1

2019-01-01

Abstract:Abstract ObjectiveThis study aimed to evaluate the therapeutic effect of caffeine citrate on early premature infants with apnea of prematurity (AOP), and the impact on movement and neurobehavioral development in their early lives.Study designAmongst 397 premature infants whose gestational age (GA) were less than 32 weeks, 172 premature infants were eligible for this study from January 2014 to May 2017. 94 infants received caffeine citrate intervention, 20 infants were given aminophyline and the rest 58 infants didn't received any methylxanthines. According to the incidence of apnea, caffeine using was divided into two situations of therapeutic and preventive administration. The primary clinical outcomes were recorded which included length of stay (LOS), duration of mechanical ventilation, the incidence of complications and outcomes.Results62 cases (66%) were assigned to receive caffeine within 3 days after birth, and 69 cases (74%) received caffeine less than one month. Caffeine could reduce LOS, duration of MV and nasal continues positive airway pressure (nCPAP), the incidence of nosocomial infection and bronchial pulmonary dysplasia (BPD) (p<0.05). There was no significant difference in the incidence of abdominal distension, necrotizing enterocolitis (NEC), patent ductus arteriosus (PDA) and intraventricular hemorrhage (IVH) compared with aminophylline and conservative groups (P >0.05). Caffeine showed different effects on clinical outcomes in early premature infants based on their GAs, and premature infants with larger GA could benefit more from the intervention (p<0.001), and caffeine didn’t affect their early lives in short-term prognosis by follow-up.Conclusion Caffeine can improve AOP clinical outcomes in those premature infants with larger GA, and didn't have side effects on the movement and neurobehavioral development in short-term prognosis.
Chordin and dickkopf-1b are essential for the formation of head structures through activation of the FGF signaling pathway in zebrafish.

Shingo Tanaka,H. Hosokawa,E. Weinberg,S. Maegawa

DOI: https://doi.org/10.1016/j.ydbio.2017.02.018

IF: 3.148

2017-04-15

Developmental Biology

Abstract:
Pharmacokinetics of Caffeine Citrate and the Progress of Its Application in the Treatment for Apnea of Prematurity

Jin-miao LU,Lin ZHU,Jing LI,Zhi-ping LI

DOI: https://doi.org/10.11669/cpj.2017.21.003

2017-01-01

Abstract:Apnea in premature infants is a common preterm neonatal serious disease,persistent apnea will cause harm to brain and organ development.Methylxanthine compounds such as theophylline and caffeine are used to treat apnea in premature infants.Among them,the caffeine treatment of greater safety and ease of administration once a day,and more attention due to caffeine safe,effective,cost-effective the best,Aranda described it as " silver bullet in neonatal medicine".Caffeine reduced the number of apneic episodes during the first 2 to 7 d and the number of intermittent positive pressure ventilation use and showed a dependency on other beneficial effects such as can reduced time of tracheal intubation and nasal catheter continuous positive airway pressure,reduce the duration of continuous oxygen supply,improve the success rate of weaning,reduce the incidence of bronchopulmonary dysplasia,reduce patent ductus arteriosus,reduce the use of hormones,retinopathy of premature children have a positive therapeutic effect.Caffeine treatment reduces positive airway pressure,thereby reducing overall treatment costs.In 2013,China approved caffeine citrate for the treatment of apnea in premature infants.In this paper,the pharmacokinetics of caffeine in premature infants and its application in apnea and related diseases of premature infants were reviewed.
Caffeine: how early is too early?

Ryan Kilpatrick,Jonathan M. Davis,Jacob V. Aranda

DOI: https://doi.org/10.1038/s41390-024-03199-z

IF: 3.953

2024-04-20

Pediatric Research

Abstract:In contrast to older children and adults, premature neonates have decreased sensitivity to carbon dioxide and often experience hypoxic ventilatory depression. This can result in deleterious and prolonged periods of hypoventilation and apnea in response to hypoxemia. Caffeine is a trimethylxanthine which stimulates the respiratory control centers in the medulla through competitive inhibition of adenosine. This increases the ventilatory responsiveness to carbon dioxide and attenuates central hypoxic ventilatory depression. For this reason, caffeine is a commonly prescribed medication administered to many premature neonates in the neonatal intensive care unit (NICU). 1 Other pharmacological effects of caffeine include enhanced diaphragmatic contractility, mild diuresis, and increased minute ventilation. Through these physiologic effects and others, caffeine has substantially reduced common morbidities among premature neonates including apnea of prematurity, bronchopulmonary dysplasia (BPD), and patent ductus arteriosus (PDA). 2 Most importantly, neonates who receive caffeine have better neurodevelopmental outcomes (e.g., less cerebral palsy and cognitive delays) and a decreased incidence of severe retinopathy of prematurity (ROP). 2,3 When considering all the medications administered in the NICU, caffeine has played a very prominent role in improving important neonatal outcomes. Caffeine has a wider therapeutic index and fewer side effects compared to other methylxanthines such as theophylline and aminophylline. 4,5 Despite the profound impact that caffeine has had on the care of premature neonates, the dosing and timing of caffeine administration has changed little since the initial trials of this groundbreaking medication several decades ago. 6 In addition, despite the widespread use of caffeine, BPD, neurodevelopmental impairment, ROP, and other morbidities continue to occur frequently in premature neonates. 7 Although the efficacy, effectiveness, and safety of caffeine are well established, questions remain about of how clinicians can devise strategies to maximize the benefits. A post hoc analyses of the Caffeine of Prematurity (CAP) Trial in 2010 demonstrated that the duration of positive pressure ventilation was significantly less with earlier treatment (started at 3 days, suggesting that earlier initiation of caffeine therapy may further improve neonatal outcomes. 8 Subsequent large cohort studies, small randomized controlled trials, and metanalyses have favored earlier caffeine administration. However, how early is too early?

pediatrics
Caffeine Preferentially Protects Against Oxygen-Induced Retinopathy

Shuya Zhang,Rong Zhou,Bo Li,Haiyan Li,Cun Wang,Yanyan Wang,Xuejiao Gu,Dingjuan Zhong,Lingyun Tang,Yuanyuan Ge,Yuqing Huo,Jing Lin,Xiao-Ling Liu,Jiang-Fan Chen

DOI: https://doi.org/10.1096/fj.201601285r

2017-01-01

Abstract:Retinopathy of prematurity (ROP) is the leading cause of childhood blindness, but current anti-VEGF therapy is concerned with delayed retinal vasculature, eye, and brain development of preterm infants. The clinical observation of reduced ROP severity in premature infants after caffeine treatment for apnea suggests that caffeine may protect against ROP. Here, we demonstrate that caffeine did not interfere with normal retinal vascularization development but selectively protected against oxygen-induced retinopathy (OIR) in mice. Moreover, caffeine attenuated not only hypoxia-induced pathologic angiogenesis, but also hyperoxia-induced vaso-obliteration, which suggests a novel protection window by caffeine. At the hyperoxic phase, caffeine reduced oxygen-induced neural apoptosis by adenosine A(2A) receptor (A(2A)R)-dependent mechanism, as revealed by combined caffeine and A(2A)R-knockout treatment. At the hypoxic phase, caffeine reduced microglial activation and enhanced tip cell formation by A(2A)R-dependent and -independent mechanisms, as combined caffeine and A(2A)R knockout produced additive and nearly full protection against OIR. Together with clinical use of caffeine in neonates, our demonstration of the selective protection against OIR, effective therapeutic window, adenosine receptor mechanisms, and neuroglial involvement provide the direct evidence of the novel effects of caffeine therapy in the prevention and treatment of ROP.
Caffeine treatment started before injury reduces hypoxic–ischemic white-matter damage in neonatal rats by regulating phenotypic microglia polarization

Liu Yang,Xuefei Yu,Yajun Zhang,Na Liu,Xindong Xue,Jianhua Fu

DOI: https://doi.org/10.1038/s41390-021-01924-6

IF: 3.953

2022-02-26

Pediatric Research

Abstract:Abstract Background Reducing neuroinflammatory damage is an effective strategy for treating white-matter damage (WMD) in premature infants. Caffeine can ameliorate hypoxia–ischemia-induced brain WMD; however, its neuroprotective effect and mechanism against hypoxic–ischemic WMD remain unclear. Methods We used 3-day-old Sprague–Dawley rats to establish a model of cerebral hypoxia–ischemia-induced brain WMD after unilateral common carotid artery ligation and hypoxia exposure (8% O 2 + 92% N 2 ) for 2.5 h. Mechanism experiments were conducted to detect M1/M2 polarization and activation of microglia and NLRP3 inflammasome. Results Caffeine inhibited NLRP3 inflammasome activation, reduced microglial Iba-1 activation, inhibited microglia M1 polarization, and promoted microglia M2 polarization by downregulating CD86 and iNOS protein expression, inhibiting the transcription of the proinflammatory TNF-α and IL-1β, upregulating CD206 and Arg-1 expression, and promoting the transcription of the anti-inflammatory factors IL-10 and TGF-β. Importantly, we found that these caffeine-mediated effects could be reversed after inhibiting A2aR activity. Conclusions Caffeine improved long-term cognitive function in neonatal rats with hypoxic–ischemic WMD via A2aR-mediated inhibition of NLRP3 inflammasome activation, reduction of microglial activation, regulation of the phenotypic polarization of microglia and the release of inflammatory factors, and improvement of myelination development. Impact The direct protective effect of caffeine on hypoxic–ischemic white-matter damage (WMD) and its mechanism remains unclear. This study elucidated this mechanism using neonatal rats as an animal model of hypoxia–ischemia-induced cerebral WMD. The findings demonstrated caffeine as a promising therapeutic tool against immature WMD to protect neonatal cognitive function. We found that caffeine pretreatment reduced WMD in immature brains via regulation of microglial activation and polarization by adenosine A2a receptor, thereby, providing a scientific basis for future clinical application of caffeine.

pediatrics
Caffeine in preterm infants: where are we in 2020?

Laura Moschino,Sanja Zivanovic,Caroline Hartley,Daniele Trevisanuto,Eugenio Baraldi,Charles Christoph Roehr

DOI: https://doi.org/10.1183/23120541.00330-2019

IF: 4.239

2020-01-01

ERJ Open Research

Abstract:The incidence of preterm birth is increasing, leading to a growing population with potential long-term pulmonary complications. Apnoea of prematurity (AOP) is one of the major challenges when treating preterm infants; it can lead to respiratory failure and the need for mechanical ventilation. Ventilating preterm infants can be associated with severe negative pulmonary and extrapulmonary outcomes, such as bronchopulmonary dysplasia (BPD), severe neurological impairment and death. Therefore, international guidelines favour non-invasive respiratory support. Strategies to improve the success rate of non-invasive ventilation in preterm infants include pharmacological treatment of AOP. Among the different pharmacological options, caffeine citrate is the current drug of choice. Caffeine is effective in reducing AOP and mechanical ventilation and enhances extubation success; it decreases the risk of BPD; and is associated with improved cognitive outcome at 2 years of age, and pulmonary function up to 11 years of age. The commonly prescribed dose (20 mg·kg −1 loading dose, 5–10 mg·kg −1 per day maintenance dose) is considered safe and effective. However, to date there is no commonly agreed standardised protocol on the optimal dosing and timing of caffeine therapy. Furthermore, despite the wide pharmacological safety profile of caffeine, the role of therapeutic drug monitoring in caffeine-treated preterm infants is still debated. This state-of-the-art review summarises the current knowledge of caffeine therapy in preterm infants and highlights some of the unresolved questions of AOP. We speculate that with increased understanding of caffeine and its metabolism, a more refined respiratory management of preterm infants is feasible, leading to an overall improvement in patient outcome.
Association of Caffeine Daily Dose With Respiratory Outcomes in Preterm Neonates: A Retrospective Cohort Study

Shahzad Rauf,Samar Shah,Zainab Bibi,Rabiya Munir,Hamna Jiskani,Saeed Ahmad,Syed Adil Mir Shah,Aysha Bibi,Hafiz Fasih Ahmad,Kashif Hussain,Shabina Ariff,Gul Ambreen

DOI: https://doi.org/10.1177/00469580241248098

2024-01-01

Abstract:Apnea and poor respiratory drive increase the risk of extubation failure (EF) and prolonged invasive mechanical ventilation (IMV) in preterm neonates (pre-nates) with respiratory distress. Caffeine citrate (CC) is often prescribed for pre-nates in doses of 5–10 mg/kg in 24 h. This study aimed to evaluate the most effective dosage regimen (5 mg/kg/day vs >5-10 mg/kg/day) to prevent apnea and EF with minimal caffeine-associated potential side effects (CC-APSEs) in pre-nates. This one-year retrospective cohort study included all the eligible neonates admitted to NICU and received CC-therapy till 28 days of life (DOL) or discharge. Based on CC-daily dose formed LD-caffeine-group (5 mg/kg/day) and HD-caffeine-group (>5-10 mg/kg/day). Antenatal, prenatal, and postnatal characteristics, CC-regimen, comorbidities, and CC-APSEs were compared between the groups. Predictors of apnea and EF were analyzed through logistic regression. There were 181 and 72 neonates in the LD and HD-caffeine-groups respectively. In HD-caffeine-group daily CC-dose was 7 to 7.5 mg/kg/day in 93% of neonates and >7.5 to 10 mg/kg/day in only 7%. Significantly fewer neonates experienced apnea and EF in the HD-caffeine-group till 28DOL or discharge. This difference was even greater in the subgroup of ≤28 weeks GA (15.6% vs 40.0%; P < .01). In HD-caffeine-group the incidence of severe/moderate-BPD was significantly lower and the frequency of CC-APSEs was higher. Multivariate analysis showed that; the smaller the GA higher the risk of apnea (AOR = 0.510, 95% CI 0.483-0.999) and EF (AOR = 0.787, 95% CI 0.411-0.997). The HD-caffeine was inversely associated with developing apnea (AOR = 0.244, 95% CI 0.053-0.291) and EF (AOR = 0.103, 95% CI 0.098-2.976). IMV-duration before extubation (AOR = 2.229, 95% CI 1.672-2.498) and severe/moderate-BPD (AOR = 2.410, 95%CI 1.104-2.952) had a high risk of EF. Initiating early HD-caffeine may prevent apnea and extubation failure in preterm neonates. Optimization of caffeine initiation time and dosages can be a safe and feasible approach to decrease the burden of neonatal respiratory morbidities.

health care sciences & services,health policy & services
Caffeine Augments Anesthesia Neurotoxicity in the Fetal Macaque Brain

Kevin K. Noguchi,Stephen A. Johnson,Francesca M. Manzella,Kobe L. Masuoka,Sasha L. Williams,Lauren D. Martin,Gregory A. Dissen,Chrysanthy Ikonomidou,Katie J. Schenning,John W. Olney,Ansgar M. Brambrink

DOI: https://doi.org/10.1038/s41598-018-23560-7

IF: 4.6

2018-03-28

Scientific Reports

Abstract:Caffeine is the most frequently used medication in premature infants. It is the respiratory stimulant of choice for apnea associated with prematurity and has been called the silver bullet in neonatology because of many proven benefits and few known risks. Research has revealed that sedative/anesthetic drugs trigger apoptotic death of neurons and oligodendrocytes in developing mammalian brains. Here we evaluated the influence of caffeine on the neurotoxicity of anesthesia in developing nonhuman primate brains. Fetal macaques (n = 7–8/group), at a neurodevelopmental age comparable to premature human infants, were exposed in utero for 5 hours to no drug (control), isoflurane, or isoflurane + caffeine and examined for evidence of apoptosis. Isoflurane exposure increased apoptosis 3.3 fold for neurons and 3.4 fold for oligodendrocytes compared to control brains. Isoflurane + caffeine caused neuronal apoptosis to increase 8.0 fold compared to control levels but did not augment oligoapoptosis. Neuronal death was particularly pronounced in the basal ganglia and cerebellum. Higher blood levels of caffeine within the range considered therapeutic and safe for human infants correlated with increased neuroapoptosis. Caffeine markedly augments neurotoxicity of isoflurane in the fetal macaque brain and challenges the assumption that caffeine is safe for premature infants.

multidisciplinary sciences
Relationship between Caffeine and Adverse Outcomes of Pregnancy

Mukun YANG,Wenpei BAI

DOI: https://doi.org/10.3969/j.issn.1007-9572.2017.03.019

2017-01-01

Abstract:Nutrition and health in pregnancy related to the maternal growth and development of the fetus and the health status after birth. Caffeine is one of the frequently contacted food and pharmaceutical compositions in everyday life,its safety in pregnancy had attracted wide attention. In this article,we summarized the results of domestic and oversea clinical researches in recent years,and finally concluded that a large quantity of caffeine intake could lead to adverse pregnancy outcomes such as low birth weight,abortion. Therefore,pregnant women should reduce caffeine intake,but not completely prohibit.
Caffeine intake during pregnancy and adverse outcomes: An integrative review

Ricardo Rohweder,Thanyse de Oliveira Schmalfuss,Diessy Dos Santos Borniger,Carolina Zanfir Ferreira,Marcos Kobren Zanardini,Guilherme Paulon Torrano Ferreira Lopes,Camila Pocharski Barbosa,Taiane Dornelles Moreira,Lavinia Schuler-Faccini,Maria Teresa Vieira Sanseverino,André Anjos da Silva,Alberto Mantovani Abeche,Fernanda Sales Luiz Vianna,Lucas Rosa Fraga

DOI: https://doi.org/10.1016/j.reprotox.2023.108518

Abstract:Caffeine intake during pregnancy is common. Caffeine crosses the placenta, raising concerns about its possible deleterious effects on the developing embryo/fetus. Studies on this subject show conflicting results, and still there is no consensus on the recommended dose of caffeine during pregnancy. We performed an integrative review with studies from six databases, using broad MESH terms to allow the identification of publications that addressed the outcomes of caffeine use during pregnancy, with no date limit for publications, in English and Portuguese language. The research returned 16,192 articles. After removing duplicates, screening by title, abstract and full-text, we evaluated 257 and included 59 articles. We found association between caffeine intake and pregnancy loss, low birth weight, cardiac and genital anomalies, higher body mass, and neurodevelopmental and neurobehavioral outcomes. The effects were often dose dependent. No association with prematurity has been demonstrated, but one study showed a small reduction in gestational age with increasing doses of caffeine intake. Defining a safe dose for caffeine intake during pregnancy is a challenging task due to the heterogeneity in study designs and results, as well as the difficulty of reliably assessing the amount of caffeine consumed. In some studies, exposures below the recommended level of caffeine intake during pregnancy (200 mg/day), as suggested by the guidelines, were associated with pregnancy loss, low birth weight, cardiac and genital anomalies, higher body mass, and neurodevelopmental and neurobehavioral outcomes. Well-designed studies with reliable quantification of caffeine intake are needed to assess the safety of low doses during pregnancy.
Gastrointestinal effects of caffeine in preterm infants: a systematic review and Bayesian meta-analysis

Beatriz Gama,Madalena von Hafe,Rafael Vieira,Henrique Soares,Inês Azevedo,Gustavo Rocha

DOI: https://doi.org/10.1136/archdischild-2024-327075

2024-04-22

Archives of Disease in Childhood - Fetal and Neonatal Edition

Abstract:Objective Caffeine is widely used in preterm infants to prevent or treat apnoea of prematurity. Adverse gastrointestinal effects of caffeine have not been thoroughly researched in preterm infants. With this systematic review and meta-analysis, we aim to summarise the results of trials on the gastrointestinal effects of caffeine in preterm infants. Design We searched MEDLINE, Web of Science, Scopus and ClinicalTrials.gov up to 21 April 2023. We included randomised controlled trials assessing caffeine versus placebo in preterm neonates and reporting gastrointestinal side effects. Risk of bias was assessed using the Cochrane Risk of Bias tool. A Bayesian meta-analysis was performed to estimate the pooled OR of gastrointestinal side effects. Results Nine trials involving 2746 preterm infants were analysed. Seven trials assessing necrotising enterocolitis and four trials assessing feeding intolerance in our meta-analysis found no differences between caffeine and placebo (OR=1.007 (95% credible interval 0.021, 5.462), I 2 =97.4%, and OR=1.266 (95% credible interval 0.064, 28.326), I 2 =84.8%, respectively). Four trials assessed the outcomes spontaneous intestinal perforation, constipation, gastrointestinal disorder (composite outcome: gastro-oesophageal regurgitation or dilated bowel loops), age at oral feeding and cholestasis syndrome and found no differences between groups. One trial assessed the outcomes gastro-oesophageal symptoms and duration of tube feeding and found that caffeine was associated with a reduced burden of gastro-oesophageal reflux symptoms at 2 weeks (p<0.05), but not at term. Conclusions According to this systematic review and meta-analysis, the use of caffeine at usual doses in preterm infants does not seem to be associated with significant gastrointestinal adverse effects.

pediatrics

The marketing of foods and non-alcoholic beverages to children. Setting the research agenda

The Babyccino: The Role of Caffeine in the Prevention of Acute Kidney Injury in Neonates—A Literature Review

Caffeine Prevents Hyperoxia-Induced Lung Injury in Neonatal Mice Through NLRP3 Inflammasome and NF-κB Pathway.

Association Between Early Caffeine Citrate Administration and Risk of Acute Kidney Injury in Preterm Neonates: Results From the AWAKEN Study

Caffeine Citrate for Apnea of Prematurity: A Prospective, Open-Label, Single-Arm Study in Chinese Neonates

Encephalopathy in Preterm Infants: Advances in Neuroprotection With Caffeine

Caffeine: The Story beyond Oxygen-Induced Lung and Brain Injury in Neonatal Animal Models—A Narrative Review

Caffeine for apnea and prevention of neurodevelopmental impairment in preterm infants: systematic review and meta-analysis

Individuals With Patellofemoral Pain Have Less Hip Flexibility Than Controls Regardless of Treatment Outcome

Caffeine citrate improves outcomes of apnea of prematurity based on gestational ages

Chordin and dickkopf-1b are essential for the formation of head structures through activation of the FGF signaling pathway in zebrafish.

Pharmacokinetics of Caffeine Citrate and the Progress of Its Application in the Treatment for Apnea of Prematurity

Caffeine: how early is too early?

Caffeine Preferentially Protects Against Oxygen-Induced Retinopathy

Caffeine treatment started before injury reduces hypoxic–ischemic white-matter damage in neonatal rats by regulating phenotypic microglia polarization

Caffeine in preterm infants: where are we in 2020?

Association of Caffeine Daily Dose With Respiratory Outcomes in Preterm Neonates: A Retrospective Cohort Study

Caffeine Augments Anesthesia Neurotoxicity in the Fetal Macaque Brain

Relationship between Caffeine and Adverse Outcomes of Pregnancy

Caffeine intake during pregnancy and adverse outcomes: An integrative review

Gastrointestinal effects of caffeine in preterm infants: a systematic review and Bayesian meta-analysis